DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Delcath Systems, Inc.

1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States

IndustryDiagnostics & Research
Full Time Employees46

Key Executives

NameTitlePayExercisedYear Born
Dr. Jennifer K. SimpsonPres, CEO & Director600.23kN/A1968
Ms. Barbra C. Keck M.B.A., MBACFO & Sec.361.65kN/A1978
Mr. John PurpuraExec. VP & Global Head of Operations408.7kN/A1961
Mr. Thomas JohnsonSr. Director of Corp. CommunicationsN/AN/AN/A
Mr. Robin WaggeSr. VP of Rubenstein AssociatesN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.